SHINE Technologies Secures EU Marketing Authorization for Lu-177 Radioisotope
SHINE Technologies has received centralised marketing authorisation (CMA) from the European Medicines Agency (EMA) for its radioisotope product Ilumira, enabling sales of non-carrier-added lutetium-177 across the EU. This regulatory approval supports targeted radioligand therapies and aligns with SHINE's broader strategy in nuclear medicine.
